Is DSGN or CLDX more profitable?

Design Therapeutics' return on equity of -34.03% beat Celldex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Design Therapeutics N/A -34.03% -32.05% Celldex Therapeutics N/A -52.35% -47.61%

Do analysts prefer GMTX or DSGN?

Design Therapeutics has a consensus target price of $16.50, indicating a potential upside of 33.50%. Given Design Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Design Therapeutics is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Design Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Which has stronger valuation and earnings, GMTX or DSGN?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A Design Therapeutics N/A N/A -$69.79M -$1.18 N/A

Is GMTX or DSGN more profitable?

Design Therapeutics' return on equity of -34.03% beat Gemini Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gemini Therapeutics N/A -38.78% -35.88% Design Therapeutics N/A -34.03% -32.05%

Is IMNM or DSGN more profitable?

Design Therapeutics' return on equity of -34.03% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -50.56% -46.93% Design Therapeutics N/A -34.03% -32.05%

Design Therapeutics (DSGN) Competitors

$12.36 +0.24 (+1.98%)

Closing price 04:00 PM Eastern

Extended Trading

$12.37 +0.01 (+0.08%)

As of 04:10 PM Eastern

Compare

DSGN vs. QURE, ZLAB, CLDX, GMTX, and IMNM

Should you buy Design Therapeutics stock or one of its competitors? Design Therapeutics's main competitors and comparable companies include uniQure (QURE), Zai Lab (ZLAB), Celldex Therapeutics (CLDX), Gemini Therapeutics (GMTX), and Immunome (IMNM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Design Therapeutics compare to uniQure?

Design Therapeutics (NASDAQ:DSGN) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

In the previous week, uniQure had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 4 mentions for uniQure and 1 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 1.82 beat uniQure's score of 0.70 indicating that Design Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Design Therapeutics	Very Positive
uniQure	Positive

56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 17.1% of Design Therapeutics shares are owned by insiders. Comparatively, 4.7% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Design Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market. Comparatively, uniQure has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Design Therapeutics has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. Design Therapeutics' return on equity of -34.03% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-34.03%	-32.05%
uniQure	-1,350.73%	-111.96%	-29.01%

Design Therapeutics presently has a consensus target price of $16.50, suggesting a potential upside of 33.50%. uniQure has a consensus target price of $59.55, suggesting a potential upside of 52.25%. Given uniQure's higher probable upside, analysts plainly believe uniQure is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
uniQure	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Design Therapeutics has higher earnings, but lower revenue than uniQure. Design Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A
uniQure	$18.67M	145.29	-$198.97M	-$4.01	N/A

Summary

Design Therapeutics beats uniQure on 9 of the 16 factors compared between the two stocks.

How does Design Therapeutics compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Design Therapeutics (NASDAQ:DSGN) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Design Therapeutics has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	6.35	-$175.54M	-$1.71	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A

In the previous week, Zai Lab had 6 more articles in the media than Design Therapeutics. MarketBeat recorded 7 mentions for Zai Lab and 1 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 1.82 beat Zai Lab's score of 0.25 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Zai Lab	Neutral
Design Therapeutics	Very Positive

Zai Lab has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market.

Zai Lab currently has a consensus price target of $37.25, suggesting a potential upside of 45.00%. Design Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 33.50%. Given Zai Lab's higher probable upside, research analysts clearly believe Zai Lab is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Design Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-41.86%	-27.43%	-16.72%
Design Therapeutics	N/A	-34.03%	-32.05%

41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 4.9% of Zai Lab shares are owned by insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Design Therapeutics beats Zai Lab on 10 of the 15 factors compared between the two stocks.

How does Design Therapeutics compare to Celldex Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Design Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 33.50%. Celldex Therapeutics has a consensus price target of $61.92, indicating a potential upside of 96.64%. Given Celldex Therapeutics' higher probable upside, analysts plainly believe Celldex Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Design Therapeutics' return on equity of -34.03% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-34.03%	-32.05%
Celldex Therapeutics	N/A	-52.35%	-47.61%

Design Therapeutics has higher earnings, but lower revenue than Celldex Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A
Celldex Therapeutics	$1.54M	1,605.79	-$258.76M	-$4.35	N/A

56.6% of Design Therapeutics shares are owned by institutional investors. 17.1% of Design Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Celldex Therapeutics had 28 more articles in the media than Design Therapeutics. MarketBeat recorded 29 mentions for Celldex Therapeutics and 1 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 1.82 beat Celldex Therapeutics' score of 0.87 indicating that Design Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Design Therapeutics	Very Positive
Celldex Therapeutics	Positive

Design Therapeutics has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

Summary

Design Therapeutics beats Celldex Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Design Therapeutics compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Design Therapeutics (NASDAQ:DSGN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market.

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A

Design Therapeutics' return on equity of -34.03% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Design Therapeutics	N/A	-34.03%	-32.05%

Design Therapeutics has a consensus target price of $16.50, indicating a potential upside of 33.50%. Given Design Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Design Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Design Therapeutics had 1 more articles in the media than Gemini Therapeutics. MarketBeat recorded 1 mentions for Design Therapeutics and 0 mentions for Gemini Therapeutics. Design Therapeutics' average media sentiment score of 1.82 beat Gemini Therapeutics' score of 0.00 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Design Therapeutics	Very Positive

Summary

Design Therapeutics beats Gemini Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Design Therapeutics compare to Immunome?

Immunome (NASDAQ:IMNM) and Design Therapeutics (NASDAQ:DSGN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Immunome has a beta of 2.13, meaning that its stock price is 113% more volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market.

Design Therapeutics' return on equity of -34.03% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-50.56%	-46.93%
Design Therapeutics	N/A	-34.03%	-32.05%

In the previous week, Immunome had 4 more articles in the media than Design Therapeutics. MarketBeat recorded 5 mentions for Immunome and 1 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 1.82 beat Immunome's score of 0.90 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Immunome	Positive
Design Therapeutics	Very Positive

44.6% of Immunome shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 7.2% of Immunome shares are held by insiders. Comparatively, 17.1% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Immunome presently has a consensus price target of $35.18, indicating a potential upside of 62.28%. Design Therapeutics has a consensus price target of $16.50, indicating a potential upside of 33.50%. Given Immunome's higher possible upside, equities research analysts clearly believe Immunome is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Design Therapeutics has lower revenue, but higher earnings than Immunome. Design Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	354.81	-$212.39M	-$2.53	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A

Summary

Design Therapeutics beats Immunome on 9 of the 15 factors compared between the two stocks.

Get Design Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DSGN vs. The Competition

Export

Metric	Design Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$773.49M	$3.96B	$7.32B	$13.03B
Dividend Yield	N/A	3.64%	2.52%	14.03%
P/E Ratio	-10.47	13.94	275.05	25.61
Price / Sales	N/A	1,305.88	662.58	108.32
Price / Cash	N/A	40.88	28.02	35.00
Price / Book	3.31	15.41	10.53	6.44
Net Income	-$69.79M	-$22.71M	$3.50B	$360.47M
7 Day Performance	-1.51%	-3.19%	-1.73%	-1.03%
1 Month Performance	-18.20%	-7.64%	-3.76%	-3.70%
1 Year Performance	88.13%	28.11%	14.48%	3.62%

Design Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DSGN Design Therapeutics	2.5159 of 5 stars	$12.36 +2.0%	$16.50 +33.5%	+84.5%	$773.49M	N/A	N/A	55	Positive News
QURE uniQure	2.7646 of 5 stars	$45.28 +2.2%	$65.00 +43.6%	-29.6%	$3.07B	$16.10M	N/A	221
ZLAB Zai Lab	2.4212 of 5 stars	$26.41 -0.1%	$37.25 +41.0%	-21.0%	$3.01B	$460.16M	N/A	1,784	Analyst Upgrade Gap Down
CLDX Celldex Therapeutics	2.4948 of 5 stars	$33.51 -11.6%	$59.17 +76.6%	+19.0%	$2.98B	$1.54M	N/A	198	Gap Down High Trading Volume
GMTX Gemini Therapeutics	N/A	$68.49 -1.5%	N/A	-0.5%	$2.97B	N/A	N/A	30	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DSGN) was last updated on 9/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Design Therapeutics (DSGN) Competitors

DSGN vs. QURE, ZLAB, CLDX, GMTX, and IMNM

How does Design Therapeutics compare to uniQure?

Summary

How does Design Therapeutics compare to Zai Lab?

Summary

How does Design Therapeutics compare to Celldex Therapeutics?

Summary

How does Design Therapeutics compare to Gemini Therapeutics?

Summary

How does Design Therapeutics compare to Immunome?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN vs. The Competition

Design Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Design Therapeutics (DSGN) Competitors

DSGN vs. QURE, ZLAB, CLDX, GMTX, and IMNM

How does Design Therapeutics compare to uniQure?

Does the media refer more to DSGN or QURE?

Do institutionals & insiders hold more shares of DSGN or QURE?

Which has more risk & volatility, DSGN or QURE?

Is DSGN or QURE more profitable?

Do analysts prefer DSGN or QURE?

Which has preferable valuation & earnings, DSGN or QURE?

Summary

How does Design Therapeutics compare to Zai Lab?

Which has higher earnings & valuation, ZLAB or DSGN?

Does the media refer more to ZLAB or DSGN?

Which has more risk & volatility, ZLAB or DSGN?

Do analysts rate ZLAB or DSGN?

Is ZLAB or DSGN more profitable?

Do insiders & institutionals hold more shares of ZLAB or DSGN?

Summary

How does Design Therapeutics compare to Celldex Therapeutics?

Do analysts recommend DSGN or CLDX?

Is DSGN or CLDX more profitable?

Which has preferable valuation & earnings, DSGN or CLDX?

Do institutionals & insiders believe in DSGN or CLDX?

Does the media refer more to DSGN or CLDX?

Which has more volatility & risk, DSGN or CLDX?

Summary

How does Design Therapeutics compare to Gemini Therapeutics?

Which has more risk and volatility, GMTX or DSGN?

Do insiders & institutionals believe in GMTX or DSGN?

Which has stronger valuation and earnings, GMTX or DSGN?

Is GMTX or DSGN more profitable?

Do analysts prefer GMTX or DSGN?

Does the media refer more to GMTX or DSGN?

Summary

How does Design Therapeutics compare to Immunome?

Which has more volatility & risk, IMNM or DSGN?

Is IMNM or DSGN more profitable?

Does the media prefer IMNM or DSGN?

Do insiders and institutionals have more ownership in IMNM or DSGN?

Do analysts rate IMNM or DSGN?

Which has higher earnings and valuation, IMNM or DSGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN vs. The Competition

Design Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools